Renaissance Technologies (RenTech)'s CADL Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 12,780 shares of Candel Therapeutics, Inc. (CADL) worth $62,622, representing 0.00% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in CADL, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 163,600 shares. Largest reduction occurred in Q3 2025, reducing 163,600 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Candel Therapeutics (CADL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Candel Therapeutics (CADL) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +12,780 | New Buy | 12,780 | $4.90 |
| Q3 2025 | -163,600 | Sold Out | 0 | $0.00 |
| Q2 2025 | +163,600 | New Buy | 163,600 | $5.06 |
| Q3 2024 | -20,600 | Sold Out | 0 | $0.00 |
| Q2 2024 | -36,305 | Reduce 63.80% | 20,600 | $6.20 |
| Q1 2024 | +38,230 | Add 204.71% | 56,905 | $1.58 |
| Q4 2023 | +18,675 | New Buy | 18,675 | $1.45 |
| Q3 2023 | -12,800 | Sold Out | 0 | $0.00 |
| Q2 2023 | -8,200 | Reduce 39.05% | 12,800 | $0.00 |
| Q1 2023 | +21,000 | New Buy | 21,000 | $0.00 |
Renaissance Technologies (RenTech)'s Candel Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Candel Therapeutics, Inc. (CADL) in Q1 2023, acquiring 21,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Candel Therapeutics, Inc. (CADL) for 10 quarters since Q1 2023.
Renaissance Technologies (RenTech)'s largest addition to Candel Therapeutics, Inc. (CADL) was in Q2 2025, adding 163,600 shares worth $827,816.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 12,780 shares of Candel Therapeutics, Inc. (CADL), valued at approximately $62,622.
As of the Q1 2026 filing, Candel Therapeutics, Inc. (CADL) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Candel Therapeutics, Inc. (CADL) was 163,600 shares, as reported at the end of Q2 2025.